Reshape Lifesciences Inc's Comment on Supply Chain
The company procures all materials, components, and related outside services for its products from qualified suppliers and contract manufacturers according to proprietary specifications. Key manufacturers and suppliers have experience with MRT technology-based products, including VT-1953 and VB-1953, which are GMP certified and regularly audited by regulatory agencies in India and the FDA. The company depends on third-party manufacturers and suppliers, and its ability to increase production relies on their experience, certification, and large-scale production capabilities. Suppliers and manufacturers are selected to supply products on a commercial scale in accordance with proprietary specifications. FDA approval may require the naming and approval of suppliers, and delays in qualifying new suppliers could adversely affect the business. Current manufacturing and supply arrangements are considered scalable to support commercial sales and clinical trials; however, scaling up production involves technical challenges and may require significant investment and hiring by suppliers. If suppliers become capacity-constrained, they may prioritize other customers, potentially impacting supply and revenue.
Reshape Lifesciences Inc's Comment on Supply Chain
The company procures all materials, components, and related outside services for its products from qualified suppliers and contract manufacturers according to proprietary specifications. Key manufacturers and suppliers have experience with MRT technology-based products, including VT-1953 and VB-1953, which are GMP certified and regularly audited by regulatory agencies in India and the FDA. The company depends on third-party manufacturers and suppliers, and its ability to increase production relies on their experience, certification, and large-scale production capabilities. Suppliers and manufacturers are selected to supply products on a commercial scale in accordance with proprietary specifications. FDA approval may require the naming and approval of suppliers, and delays in qualifying new suppliers could adversely affect the business. Current manufacturing and supply arrangements are considered scalable to support commercial sales and clinical trials; however, scaling up production involves technical challenges and may require significant investment and hiring by suppliers. If suppliers become capacity-constrained, they may prioritize other customers, potentially impacting supply and revenue.
Sources:
Reshape Lifesciences Inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Reshape Lifesciences Inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
